Cardio Diagnostics Holdings, Inc. SEC filings CDIO
Cardio Diagnostics Holdings, Inc. has 295 filings in SEC EDGAR's recent list, going back to Jul 20, 2021. Its latest annual report, Form ARS, was filed on Jul 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 18, 2026 (shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 20, 2026 | Aug 20, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 19, 2026 | Feb 19, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2025 | Oct 15, 2025 |
| 8-K |
Current report
Other events
|
May 28, 2025 | May 28, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
May 13, 2025 | May 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 21, 2025 | Feb 21, 2025 |
| 8-K |
Current report
Listing notice
|
Dec 4, 2024 | Dec 4, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Nov 18, 2024 | Nov 15, 2024 |
| 8-K |
Current report
Listing notice
|
Jun 7, 2024 | Jun 3, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 2, 2024 | Apr 2, 2024 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Feb 2, 2024 | Feb 2, 2024 |
| 8-K |
Current report
Material agreement
|
Feb 1, 2024 | Jan 26, 2024 |
| 8-K |
Current report
Agreement ended
|
Jan 4, 2024 | Jan 4, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Dec 19, 2023 | Dec 18, 2023 |
| 8-K |
Current report
Other events
|
Dec 6, 2023 | Dec 5, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 22, 2023 | Nov 20, 2023 |
| 8-K |
Current report
Listing notice
|
Sep 25, 2023 | Sep 21, 2023 |
| 8-K/A |
Amended current report
Material agreement, New debt, Unregistered share sale
|
Sep 14, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 11, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change
|
Jun 22, 2023 | Jun 19, 2023 |
| 8-K/A |
Amended current report
Material agreement, New debt, Unregistered share sale
|
Jun 5, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 30, 2023 | May 26, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 16, 2023 | May 16, 2023 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Regulation FD disclosure, Other events
|
Mar 13, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Auditor change
|
Nov 10, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Listing notice, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 31, 2022 | Oct 25, 2022 |
| 8-K |
Current report
New debt, Other events
|
Sep 23, 2022 | Sep 22, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 21, 2022 | Sep 21, 2022 |
| 8-K |
Current report
Material agreement
|
Sep 15, 2022 | Sep 15, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2022 | Aug 26, 2022 |
| 8-K |
Current report
New debt, Other events
|
Aug 25, 2022 | Aug 23, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
May 31, 2022 | May 27, 2022 |
| 8-K |
Current report
Auditor change
|
Jan 25, 2022 | Jan 19, 2022 |
| 8-K |
Current report
Other events
|
Jan 12, 2022 | Jan 12, 2022 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Dec 6, 2021 | Nov 30, 2021 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Dec 3, 2021 | Nov 26, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Nov 26, 2021 | Nov 22, 2021 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CDIO (Nasdaq), CDIOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870144
- Former names
- Mana Capital Acquisition Corp. (until Oct 26, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.